Mergerplay (Seite 13)
eröffnet am 02.11.17 21:13:52 von
neuester Beitrag 02.11.22 16:26:10 von
neuester Beitrag 02.11.22 16:26:10 von
Beiträge: 353
ID: 1.266.182
ID: 1.266.182
Aufrufe heute: 0
Gesamt: 38.415
Gesamt: 38.415
Aktive User: 0
ISIN: US30048L2034 · WKN: A3DL69
0,1860
EUR
0,00 %
0,0000 EUR
Letzter Kurs 05.10.22 L&S Exchange
Neuigkeiten
18.12.23 · Business Wire (engl.)  |
12.12.23 · Business Wire (engl.) |
12.12.23 · Business Wire (engl.) |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5700 | +55,23 | |
| 5,4500 | +41,56 | |
| 141,00 | +41,00 | |
| 1,1500 | +34,98 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 12,150 | -12,72 | |
| 35,69 | -13,71 | |
| 29,40 | -16,95 | |
| 5,2500 | -19,23 | |
| 0,7300 | -19,34 |
Beitrag zu dieser Diskussion schreiben
Feedback
ATL fast geknackt.
Hier geht was.
Hier geht was.
Deshalb setzen die Abverkäufe bei 2,60 ein.
Sieht gut aus?
Aber meine paar Teile sind sowieso uninteressant und deshalb lasse ich sie liegen.
Mal abwarten, vielleicht kommt hier ja bald der "Wendehammer"
Sieht gut aus?
Aber meine paar Teile sind sowieso uninteressant und deshalb lasse ich sie liegen.
Mal abwarten, vielleicht kommt hier ja bald der "Wendehammer"
Gute PR für Phexxi...
Viral TikTok Highlights How Birth Control Pills Have Higher Blood Clot Risk Than AstraZeneca Vaccine
3/19/21
https://www.newsweek.com/viral-tiktok-highlights-how-birth-c…
Scientists probe new theories on whether AstraZeneca shot linked to blood clots
March 20, 2021
“…others are trying to understand whether the cases are linked with birth control pills.”
https://www.reuters.com/article/us-health-coronavirus-vaccin…
Viral TikTok Highlights How Birth Control Pills Have Higher Blood Clot Risk Than AstraZeneca Vaccine
3/19/21
https://www.newsweek.com/viral-tiktok-highlights-how-birth-c…
Scientists probe new theories on whether AstraZeneca shot linked to blood clots
March 20, 2021
“…others are trying to understand whether the cases are linked with birth control pills.”
https://www.reuters.com/article/us-health-coronavirus-vaccin…
Most Undervalued Biotech Is a Non-Hormonal Birth Control Gel
March 17, 2021
https://lastfuturist.com/most-undervalued-biotech-is-a-non-h…
March 17, 2021
https://lastfuturist.com/most-undervalued-biotech-is-a-non-h…
March 17, 2021
https://evofem.investorroom.com/2021-03-17-Evofem-Bioscience…
Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact
- Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month -
- Accelerating retail demand drove 73% increase in ex-factory sales month-over-month -
- Ex-factory sales YTD 2021 through mid-March have exceeded FY 2020 levels -
https://evofem.investorroom.com/2021-03-17-Evofem-Bioscience…
Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact
- Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month -
- Accelerating retail demand drove 73% increase in ex-factory sales month-over-month -
- Ex-factory sales YTD 2021 through mid-March have exceeded FY 2020 levels -
Trading Spotlight
Eigentlich wollte ich ja auch verkaufen.
Aber ich habe in dem Absturz nochmal nachgelegt.
Mal sehen, wird schon werden.
Aber ich habe in dem Absturz nochmal nachgelegt.
Mal sehen, wird schon werden.
Antwort auf Beitrag Nr.: 67.433.204 von iknowtheway am 12.03.21 13:48:49Ja verfolge ich auch seit ein paar Wochen. Ich denke in der Tabelle sind die Refill-werte wichtig, da ja momentan viele "Erstkunden" eine Gratispackung erhalten. Diejenigen die damit zufrieden sind und dabei bleiben, sollten deshalb in der RRX Zahl ersichtlich sein. Zumindest lässt sich bis jetzt eine Aufwärtskrümmung erahnen, hoffen wir mal, dass die durch die aktuelle Werbung der Anstieg in den nächsten Wochen noch deutlicher wird.
Heute auf Stocktwits gefunden...
BBG numbers week 3/05
Total prescription: 1072
New presciption: 974
Total quantity:64.25k
New quantity: 58.25k
Total dollars: 327.31k
New dollars: 297.62k
BBG numbers week 3/05
Total prescription: 1072
New presciption: 974
Total quantity:64.25k
New quantity: 58.25k
Total dollars: 327.31k
New dollars: 297.62k
Form 4 - Statement of changes in beneficial ownership of securities
March 9, 2021
https://app.quotemedia.com/data/downloadFiling?webmasterId=1…
PELLETIER SAUNDRA L
Purchase of 45,249 shares at $2.28
March 9, 2021
https://app.quotemedia.com/data/downloadFiling?webmasterId=1…
PELLETIER SAUNDRA L
Purchase of 45,249 shares at $2.28
Evofem Biosciences Launches Phexxi: Will Peak Sales Surprise?
Mar. 09, 2021
https://seekingalpha.com/article/4412637-evofem-biosciences-…
Conclusion
Evofem shares appear to be undervalued as there is a clear need for Phexxi, which is safe and effective, a potential trend towards non hormonal birth control, an experienced executive sales and marketing team, a motivated sales force, and a billion dollar opportunity. The company will most likely need to find a way to further finance its Phexxi launch, and sales need to prove themselves as this is a new category of birth control and it needs to further obtain favorable insurance coverage for Phexxi. However, once these three things are done, I think the trend will be Evofem's friend, and sales have a good chance of surprising to the upside. There also could be substantial opportunity outside the U.S. to bring additional upside to Phexxi sales. I am cautiously optimistic on Phexxi's long term sales, and I certainly hope for their success for the benefit of women who have suffered.
Mar. 09, 2021
https://seekingalpha.com/article/4412637-evofem-biosciences-…
Conclusion
Evofem shares appear to be undervalued as there is a clear need for Phexxi, which is safe and effective, a potential trend towards non hormonal birth control, an experienced executive sales and marketing team, a motivated sales force, and a billion dollar opportunity. The company will most likely need to find a way to further finance its Phexxi launch, and sales need to prove themselves as this is a new category of birth control and it needs to further obtain favorable insurance coverage for Phexxi. However, once these three things are done, I think the trend will be Evofem's friend, and sales have a good chance of surprising to the upside. There also could be substantial opportunity outside the U.S. to bring additional upside to Phexxi sales. I am cautiously optimistic on Phexxi's long term sales, and I certainly hope for their success for the benefit of women who have suffered.
Durchsuchen
